Pan-European Electronic Dealing System Planned

23 January 1995

by Jean Moran

The most challenging step for the management of a growth company to take is when seeking a first-time stock market flotation or initial public offering. Young, entrepreneurial companies, including those in the health care sector, are taking note of plans by most European countries to improve their access to equity capital. An additional proposal is for a new, pan-European electronic dealing system (EASDAQ), featuring growth companies in all business sectors, planned to be in operation by end-1995.

The European Association of Securities Dealers, launched late in 1994, is involved in a cooperative venture to aid young cash-seeking enterprises, especially fast-growers in the high-technology, biotechnology and bioscience sectors. Created by the Capital Markets Working Group, including US and European stock market participants brought together by the European Venture Capital Association and backed by the European Commission, it aims "to promote equity investment in growth enterprises." the EASD's Jonathan Freeman says this is an important initiative in view of the European Commission Directives on financial services, which must be implemented this year. Just as the European Medicines Evaluation Agency aims to harmonize EU regulatory requirements, these financial directives will help evolve a system of mutual recognition for financial transactions, and facilitate cross-border trading in stocks and shares, he says.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight